How to choose a microarray service provider
Oxford Gene Technology (OGT), provider of innovative genetics and biomarker solutions to advance molecular medicine, has recently published a whitepaper entitled “10 essential questions to ask your microarray service provider”. The document, which is available to download, suggests the 10 most important questions a researcher should ask when identifying which microarray service best meets their experimental requirements.
Each service provider is different, offering varying levels of experience and expertise, with some catering for many different applications and others dedicated only to specific areas. This often includes the ability to offer consultancy on various aspects of a study, such as suggesting ways to optimise array and experiment design, sample screening processes and data analysis. In addition, providers use a variety of array platforms and quality control methods, each affecting their suitability for different project requirements. These factors are highly important when deciding on the best service provider to utilise.
The whitepaper provided by OGT will help researchers make better informed decisions when it comes to choosing a microarray service provider, and can be downloaded for free.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: email@example.com
Notes for editors:
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.